Identification

Name
Busulfan
Accession Number
DB01008  (APRD00664)
Type
Small Molecule
Groups
Approved, Investigational
Description

Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. [PubChem]

Structure
Thumb
Synonyms
  • 1,4-Bis(methanesulfonoxy)butane
  • 1,4-Butanediol dimethanesulfonate
  • 1,4-Dimesyloxybutane
  • 1,4-Dimethanesulfonoxybutane
  • Bisulfex
  • Busulfan
  • Busulfano
  • Busulfanum
  • Leucosulfan
  • Mablin
  • Mielucin
  • Misulban
  • Mitostan
  • Myeloleukon
  • Tetramethylene bis(methanesulfonate)
External IDs
NCI-C01592 / NSC-750
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Busulfan for InjectionSolution6 mgIntravenousSterimax Inc2017-10-04Not applicableCanada
BusulfexInjection6 mg/mLIntravenousOtsuka Pharmaceutical Co., Ltd.1999-02-04Not applicableUs
BusulfexSolution6 mgIntravenousOtsuka Pharmaceutical Co., Ltd.1999-09-23Not applicableCanada
BusulfexInjection6 mg/mLIntravenousOtsuka Pharmaceutical Co., Ltd.2015-02-13Not applicableUs
MyleranTablet, film coated2 mg/1OralAspen Global Inc.1985-03-21Not applicableUs
MyleranTablet2 mgOralAspen Pharmacare Canada Inc.1954-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BusulfanInjection, solution, concentrate6 mg/mLIntravenousSagent Pharmaceuticals2017-05-15Not applicableUs
BusulfanInjection6 mg/mLIntravenousPharmascience Inc.2017-05-19Not applicableUs
N/aInjection6 mg/mLIntravenousAmerican Regent2017-04-01Not applicableUs
International/Other Brands
Busilvex (Pierre Fabre) / Myleran
Categories
UNII
G1LN9045DK
CAS number
55-98-1
Weight
Average: 246.302
Monoisotopic: 246.02317956
Chemical Formula
C6H14O6S2
InChI Key
COVZYZSDYWQREU-UHFFFAOYSA-N
InChI
InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
IUPAC Name
4-(methanesulfonyloxy)butyl methanesulfonate
SMILES
CS(=O)(=O)OCCCCOS(C)(=O)=O

Pharmacology

Indication

For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.

Structured Indications
Pharmacodynamics

Busulfan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn leads to a miscoding of DNA. Alkylating agents are cell cycle-nonspecific and work by three different mechanisms, all of which achieve the same end result - disruption of DNA function and cell death. Overexpression of MGST2, a glutathione s-transferase, is thought to confer resistance to busulfan. The role of MGST2 in the metabolism of busulfan is unknown however.

Mechanism of action

Busulfan is an alkylating agent that contains 2 labile methanesulfonate groups attached to opposite ends of a 4-carbon alkyl chain. Once busulfan is hydrolyzed, the methanesulfonate groups are released and carbonium ions are produced. These carbonium ions alkylate DNA, which results in the interference of DNA replication and RNA transcription, ultimately leading to the disruption of nucleic acid function. Specifically, its mechanism of action through alkylation produces guanine-adenine intrastrand crosslinks. This occurs through an SN2 reaction in which the relatively nucleophilic guanine N7 attacks the carbon adjacent to the mesylate leaving group. This kind of damage cannot be repaired by cellular machinery and thus the cell undergoes apoptosis.

TargetActionsOrganism
ADNA
cross-linking/alkylation
Human
Absorption

Completely absorbed from the gastrointestinal tract. Busulfan is a small, highly lipophilic molecule that crosses the blood-brain-barrier. The absolute bioavailability, if a single 2 mg IV bolus injection is given to adult patients, is 80% ± 20%. In children (1.5 - 6 years old), the absolute bioavailability was 68% ± 31%. When a single oral dose is given to patients, the area under the curve (AUC) was 130 ng•hr/mL. The peak plasma concentration when given orally is 30 ng/mL (after dose normalization to 2 mg). It takes 0.9 hours to reach peak plasma concentration after dose normalization to 4 mg.

Volume of distribution
Not Available
Protein binding

32% bound to plasma proteins and 47% bound to red blood cells.

Metabolism

Busulfan is extensively metabolizes in the hepatic. Busulfan is predominantly metabolized by conjugation with glutathione, both spontaneously and by glutathione S-transferase (GST) catalysis. GSTA1 is the primary GST isoform that facilitates the the metabolism of busulfan. Other GST isoforms that are also involved are GSTM1 and GSTP1. At least 12 metabolites have been identified among which tetrahydrothiophene, tetrahydrothiophene 12-oxide, sulfolane, and 3-hydroxysulfolane were identified. These metabolites do not have cytotoxic activity.

Route of elimination

Following administration of 14C- labeled busulfan to humans, approximately 30% of the radioactivity was excreted into the urine over 48 hours; negligible amounts were recovered in feces. Less than 2% of the administered dose is excreted in the urine unchanged within 24 hours. Elimination of busulfan is independent of renal function.

Half life

2.6 hours

Clearance
  • 2.52 ml/min/kg [Following an infusion of dose of 0.8 mg/kg every six hours, for a total of 16 doses over four days]
Toxicity

Signs of overdose include allergic reaction, unusual bleeding or bruising, sudden weakness or unusual fatigue, persistent cough, congestion, or shortness of breath; flank, stomach or joint pain; pronounced nausea, vomiting, diarrhea, dizziness, confusion, or darkening of the skin, chills, fever, collapse, and loss of consciousness.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe serum concentration of Busulfan can be increased when it is combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe serum concentration of Busulfan can be increased when it is combined with 2-mercaptobenzothiazole.Vet Approved
AcetaminophenThe serum concentration of Busulfan can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Busulfan.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Busulfan.Experimental
AmiodaroneThe metabolism of Busulfan can be decreased when combined with Amiodarone.Approved, Investigational
AmorolfineThe serum concentration of Busulfan can be increased when it is combined with Amorolfine.Approved, Investigational
Amphotericin BThe serum concentration of Busulfan can be increased when it is combined with Amphotericin B.Approved, Investigational
AnidulafunginThe serum concentration of Busulfan can be increased when it is combined with Anidulafungin.Approved, Investigational
AprepitantThe serum concentration of Busulfan can be increased when it is combined with Aprepitant.Approved, Investigational
ArtemetherThe serum concentration of Busulfan can be increased when it is combined with Artemether.Approved
AtazanavirThe metabolism of Busulfan can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Busulfan can be decreased when combined with Atomoxetine.Approved
Bafilomycin A1The serum concentration of Busulfan can be increased when it is combined with Bafilomycin A1.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Busulfan.Investigational
Benzoic AcidThe serum concentration of Busulfan can be increased when it is combined with Benzoic Acid.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Busulfan.Approved, Investigational
BifonazoleThe serum concentration of Busulfan can be increased when it is combined with Bifonazole.Approved, Investigational
BoceprevirThe metabolism of Busulfan can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Busulfan can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Busulfan can be decreased when it is combined with Bosentan.Approved, Investigational
Brefeldin AThe serum concentration of Busulfan can be increased when it is combined with 1,6,7,8,9,11A,12,13,14,14A-DECAHYDRO-1,13-DIHYDROXY-6-METHYL-4H-CYCLOPENT[F]OXACYCLOTRIDECIN-4-ONE.Experimental
ButenafineThe serum concentration of Busulfan can be increased when it is combined with Butenafine.Approved
ButoconazoleThe serum concentration of Busulfan can be increased when it is combined with Butoconazole.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Busulfan.Approved
CandicidinThe serum concentration of Busulfan can be increased when it is combined with Candicidin.Withdrawn
Capric acidThe serum concentration of Busulfan can be increased when it is combined with Capric acid.Experimental
CarbamazepineThe metabolism of Busulfan can be increased when combined with Carbamazepine.Approved, Investigational
CaspofunginThe serum concentration of Busulfan can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Busulfan can be increased when it is combined with Ceritinib.Approved
CeruleninThe serum concentration of Busulfan can be increased when it is combined with Cerulenin.Approved
ChloroxineThe serum concentration of Busulfan can be increased when it is combined with Chloroxine.Approved
CiclopiroxThe serum concentration of Busulfan can be increased when it is combined with Ciclopirox.Approved, Investigational
ClarithromycinThe metabolism of Busulfan can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Busulfan can be decreased when combined with Clemastine.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Busulfan.Approved
ClotrimazoleThe serum concentration of Busulfan can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Busulfan is combined with Clozapine.Approved
CobicistatThe metabolism of Busulfan can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Busulfan can be increased when it is combined with Conivaptan.Approved, Investigational
CordycepinThe serum concentration of Busulfan can be increased when it is combined with Cordycepin.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Busulfan.Approved
CrizotinibThe metabolism of Busulfan can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Busulfan.Approved, Investigational
CyclosporineThe serum concentration of Busulfan can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Busulfan.Experimental
DabrafenibThe serum concentration of Busulfan can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Busulfan can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Busulfan can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Busulfan can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Busulfan can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Busulfan.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Busulfan.Approved
DichloropheneThe serum concentration of Busulfan can be increased when it is combined with Dichlorophene.Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Busulfan.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Busulfan.Approved
DihydroergotamineThe metabolism of Busulfan can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Busulfan can be decreased when combined with Diltiazem.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Busulfan.Approved, Investigational
DoxycyclineThe metabolism of Busulfan can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Busulfan can be decreased when combined with Dronedarone.Approved
EconazoleThe serum concentration of Busulfan can be increased when it is combined with Econazole.Approved
EfinaconazoleThe serum concentration of Busulfan can be increased when it is combined with Efinaconazole.Approved
EnzalutamideThe serum concentration of Busulfan can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Busulfan can be decreased when combined with Erythromycin.Approved, Vet Approved
FenticonazoleThe serum concentration of Busulfan can be increased when it is combined with Fenticonazole.Experimental
FingolimodBusulfan may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Busulfan can be increased when it is combined with Fluconazole.Approved
FlucytosineThe serum concentration of Busulfan can be increased when it is combined with Flucytosine.Approved
FlutrimazoleThe serum concentration of Busulfan can be increased when it is combined with Flutrimazole.Experimental
FluvoxamineThe metabolism of Busulfan can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Busulfan can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Busulfan can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Busulfan can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Busulfan can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Busulfan.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Busulfan.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Busulfan.Experimental
GlyphosateThe serum concentration of Busulfan can be increased when it is combined with Glyphosate.Experimental
GriseofulvinThe serum concentration of Busulfan can be increased when it is combined with Griseofulvin.Approved, Vet Approved
HachimycinThe serum concentration of Busulfan can be increased when it is combined with Hachimycin.Experimental
HaloproginThe serum concentration of Busulfan can be increased when it is combined with Haloprogin.Approved, Withdrawn
HexetidineThe serum concentration of Busulfan can be increased when it is combined with Hexetidine.Approved, Investigational
IdelalisibThe serum concentration of Busulfan can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Busulfan is combined with Ifosfamide.Approved
ImatinibThe metabolism of Busulfan can be decreased when combined with Imatinib.Approved
IndinavirThe metabolism of Busulfan can be decreased when combined with Indinavir.Approved
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Busulfan.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Busulfan.Investigational
IsavuconazoniumThe metabolism of Busulfan can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe serum concentration of Busulfan can be increased when it is combined with Isoconazole.Approved
IsradipineThe metabolism of Busulfan can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Busulfan can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Busulfan can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Busulfan can be increased when it is combined with Ketoconazole.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Busulfan.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Busulfan is combined with Leflunomide.Approved, Investigational
LopinavirThe metabolism of Busulfan can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Busulfan can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Busulfan can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Busulfan can be increased when combined with Lumacaftor.Approved
MepartricinThe serum concentration of Busulfan can be increased when it is combined with Mepartricin.Experimental
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Busulfan.Investigational, Withdrawn
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Busulfan.Experimental
MetronidazoleThe serum concentration of Busulfan can be increased when it is combined with Metronidazole.Approved
MevastatinThe serum concentration of Busulfan can be increased when it is combined with Mevastatin.Experimental
MicafunginThe serum concentration of Busulfan can be increased when it is combined with Micafungin.Approved, Investigational
MiconazoleThe serum concentration of Busulfan can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Busulfan can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe serum concentration of Busulfan can be increased when it is combined with Miltefosine.Approved
MitotaneThe serum concentration of Busulfan can be decreased when it is combined with Mitotane.Approved
MonensinThe serum concentration of Busulfan can be increased when it is combined with Monensin.Vet Approved
MyxothiazolThe serum concentration of Busulfan can be increased when it is combined with Myxothiazol.Experimental
NaftifineThe serum concentration of Busulfan can be increased when it is combined with Naftifine.Approved
NatalizumabThe risk or severity of adverse effects can be increased when Busulfan is combined with Natalizumab.Approved, Investigational
NatamycinThe serum concentration of Busulfan can be increased when it is combined with Natamycin.Approved
NefazodoneThe metabolism of Busulfan can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Busulfan can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Busulfan can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Busulfan can be increased when combined with Nevirapine.Approved
NifuratelThe serum concentration of Busulfan can be increased when it is combined with Nifuratel.Experimental
Nikkomycin ZThe serum concentration of Busulfan can be increased when it is combined with Nikkomycin Z.Investigational
NilotinibThe metabolism of Busulfan can be decreased when combined with Nilotinib.Approved, Investigational
NitroxolineThe serum concentration of Busulfan can be increased when it is combined with Nitroxoline.Approved
NystatinThe serum concentration of Busulfan can be increased when it is combined with Nystatin.Approved, Vet Approved
OlaparibThe metabolism of Busulfan can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Busulfan.Experimental, Investigational
OmoconazoleThe serum concentration of Busulfan can be increased when it is combined with Omoconazole.Experimental
OsimertinibThe serum concentration of Busulfan can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Busulfan.Approved
OxiconazoleThe serum concentration of Busulfan can be increased when it is combined with Oxiconazole.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Busulfan.Approved, Vet Approved
pafuramidineThe serum concentration of Busulfan can be increased when it is combined with pafuramidine.Investigational
PalbociclibThe serum concentration of Busulfan can be increased when it is combined with Palbociclib.Approved
PentamidineThe serum concentration of Busulfan can be increased when it is combined with Pentamidine.Approved
PentobarbitalThe metabolism of Busulfan can be increased when combined with Pentobarbital.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Busulfan.Experimental
PhenobarbitalThe metabolism of Busulfan can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Busulfan can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Busulfan.Approved, Investigational
PosaconazoleThe serum concentration of Busulfan can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Busulfan can be increased when combined with Primidone.Approved, Vet Approved
PropacetamolThe serum concentration of Busulfan can be increased when it is combined with Propacetamol.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Busulfan.Experimental
PyrrolnitrinThe serum concentration of Busulfan can be increased when it is combined with Pyrrolnitrin.Experimental
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Busulfan is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Busulfan.Approved
RadicicolThe serum concentration of Busulfan can be increased when it is combined with Radicicol.Experimental
RanolazineThe metabolism of Busulfan can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Busulfan can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Busulfan can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Busulfan can be increased when combined with Rifapentine.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Busulfan.Investigational
RitonavirThe metabolism of Busulfan can be decreased when combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Busulfan.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Busulfan.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Busulfan.Approved
Salicylhydroxamic AcidThe serum concentration of Busulfan can be increased when it is combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe serum concentration of Busulfan can be increased when it is combined with Salicylic acid.Approved, Vet Approved
SaquinavirThe metabolism of Busulfan can be decreased when combined with Saquinavir.Approved, Investigational
SertaconazoleThe serum concentration of Busulfan can be increased when it is combined with Sertaconazole.Approved
SildenafilThe metabolism of Busulfan can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Busulfan can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Busulfan can be increased when it is combined with Simeprevir.Approved
SinefunginThe serum concentration of Busulfan can be increased when it is combined with Sinefungin.Experimental
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Busulfan.Approved
SirolimusThe serum concentration of Busulfan can be increased when it is combined with Sirolimus.Approved, Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Busulfan.Investigational
St. John's WortThe serum concentration of Busulfan can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Busulfan can be increased when it is combined with Stiripentol.Approved
SulconazoleThe serum concentration of Busulfan can be increased when it is combined with Sulconazole.Approved
SulfisoxazoleThe metabolism of Busulfan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Busulfan.Approved, Investigational
TavaboroleThe serum concentration of Busulfan can be increased when it is combined with Tavaborole.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Busulfan.Investigational
TelaprevirThe metabolism of Busulfan can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Busulfan can be decreased when combined with Telithromycin.Approved
TerbinafineThe serum concentration of Busulfan can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe serum concentration of Busulfan can be increased when it is combined with Terconazole.Approved
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Busulfan.Investigational
ThymolThe serum concentration of Busulfan can be increased when it is combined with Thymol.Approved
TiclopidineThe metabolism of Busulfan can be decreased when combined with Ticlopidine.Approved
TioconazoleThe serum concentration of Busulfan can be increased when it is combined with Tioconazole.Approved
TocilizumabThe serum concentration of Busulfan can be decreased when it is combined with Tocilizumab.Approved
TofacitinibBusulfan may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolciclateThe serum concentration of Busulfan can be increased when it is combined with Tolciclate.Experimental
TolnaftateThe serum concentration of Busulfan can be increased when it is combined with Tolnaftate.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Busulfan.Approved, Investigational
TrimetrexateThe serum concentration of Busulfan can be increased when it is combined with Trimetrexate.Approved, Investigational
VenlafaxineThe metabolism of Busulfan can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Busulfan can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Busulfan can be increased when it is combined with Voriconazole.Approved, Investigational
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Busulfan.Approved
ZiprasidoneThe metabolism of Busulfan can be decreased when combined with Ziprasidone.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Busulfan.Approved
Food Interactions
  • Drink liberally.
  • Take without regard to meals.

References

Synthesis Reference

Timmis, G.M.; U S . Patent 2,917,432; December 15, 1959; assigned to Burroughs Wellcome & Co., Inc.

US2917432
General References
  1. Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, Bader M, Clavien PA: Platelet-derived serotonin mediates liver regeneration. Science. 2006 Apr 7;312(5770):104-7. [PubMed:16601191]
  2. Valdez BC, Andersson BS: Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environ Mol Mutagen. 2010 Jul;51(6):659-68. doi: 10.1002/em.20603. [PubMed:20577993]
  3. Hall AG, Tilby MJ: Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev. 1992 Sep;6(3):163-73. [PubMed:1422285]
  4. Ciurea SO, Andersson BS: Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 May;15(5):523-36. doi: 10.1016/j.bbmt.2008.12.489. Epub 2009 Feb 12. [PubMed:19361744]
  5. McCune JS, Holmberg LA: Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):957-69. doi: 10.1517/17425250903107764. [PubMed:19611402]
  6. Krivoy N, Hoffer E, Lurie Y, Bentur Y, Rowe JM: Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children. Curr Drug Saf. 2008 Jan;3(1):60-6. [PubMed:18690982]
  7. Nath CE, Shaw PJ: Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol. 2007 Jan;2(1):75-91. [PubMed:18690856]
External Links
Human Metabolome Database
HMDB15143
KEGG Drug
D00248
KEGG Compound
C06862
PubChem Compound
2478
PubChem Substance
46506234
ChemSpider
2384
ChEBI
28901
ChEMBL
CHEMBL820
PharmGKB
PA448691
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Busulfan
ATC Codes
L01AB01 — Busulfan
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (50.7 KB)
MSDS
Download (67.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentAdult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
0RecruitingTreatmentX-Linked Chronic Granulomatious Disease1
1Active Not RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentBlood And Marrow Transplantation / Leukemias / Malignant Lymphomas / Transplantation Infection / Transplantation, Bone Marrow1
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentBrain and Central Nervous System Tumors / Childhood Germ Cell Tumor / Leukemias / Malignant Lymphomas / Metastatic Cancers / Retinoblastoma / Sarcomas1
1CompletedTreatmentChronic / Granulomatous Disease1
1CompletedTreatmentEndometriosis1
1CompletedTreatmentEwing's Sarcoma (ES)1
1CompletedTreatmentHematopoietic Stem Cell Transplantation (HSCT)1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)2
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphoblastic, Acute1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes2
1CompletedTreatmentLeukemias / Malignant Lymphomas / Plasma Cell Myeloma1
1CompletedTreatmentLeukemias / Myelodysplastic Syndrome2
1CompletedTreatmentMalignant Lymphomas1
1CompletedTreatmentNeuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentOsteogenesis Imperfecta1
1CompletedTreatmentSarcomas1
1RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Agnogenic Myeloid Metaplasia / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Malignancies, Hematologic / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Syndromes / Non Hodgkin Lymphoma (NHL)1
1RecruitingTreatmentAgnogenic Myeloid Metaplasia / Hematological Diseases / Immune Deficiencies / Malignant Lymphomas / Multiple Myeloma (MM) / Tumors, Solid1
1RecruitingTreatmentAgnogenic Myeloid Metaplasia / Leukemia, Lymphocytic / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Myeloid Leukemias / Waldenstrom's Macroglobulinemia (WM)1
1RecruitingTreatmentAplastic Anaemia (AA) / Chronic Leukemias / Congenital Hematological Disorder / Immune Deficiency Disorder / Leukaemia, Acute / Malignant Lymphomas / Metabolism Disorder / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Tumors, Solid1
1RecruitingTreatmentClear Cell Carcinoma / Ewing's Sarcoma (ES) / Gastrointestinal Tumors / Germ Cell Tumors / Hepatic Tumors / Malignant Lymphomas / Melanoma / Neuroblastomas / Non-rhabdomyosarcoma / Renal Cell Adenocarcinoma / Rhabdoid Tumors / Rhabdomyosarcomas / Wilms' tumor1
1RecruitingTreatmentHLA-A*0201 Positive Cells Present / Locally Advanced Malignant Neoplasm / NY-ESO-1 Positive / Unresectable Malignant Neoplasm1
1RecruitingTreatmentHigh-risk Tumor / Malignant Lymphomas / Neuroblastomas1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentLeukemias1
1TerminatedSupportive CareBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Chordomas / Liver Cancer / Neuroblastomas / Renal Cancers / Retinoblastoma / Sarcomas1
1TerminatedTreatmentBrain and Central Nervous System Tumors / Liver Cancer / Renal Cancers / Retinoblastoma / Sarcomas1
1TerminatedTreatmentJuvenile Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1TerminatedTreatmentNeuroblastomas1
1TerminatedTreatmentSclerosis, Progressive Systemic / Systemic Lupus Erythematosus (SLE)1
1Unknown StatusTreatmentMelanoma (Skin)1
1Unknown StatusTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1WithdrawnTreatmentCancer, Breast / Lung Cancers / Melanoma (Skin) / Renal Cancers / Testicular germ cell tumour1
1WithdrawnTreatmentEwing's Sarcoma (ES)1
1WithdrawnTreatmentRefractory Brain Tumors1
1, 2Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1, 2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts1
1, 2Active Not RecruitingTreatmentAdvanced Cancers / Malignant Lymphomas1
1, 2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
1, 2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
1, 2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Plasma Cell Myeloma1
1, 2CompletedNot AvailableSevere Combined Immunodeficiency / T-Cell Immune Deficiency Diseases1
1, 2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias / Malignant Lymphomas1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Thrombocytopenias1
1, 2CompletedTreatmentCongenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Leukemias / Severe Congenital Neutropenia / Thrombocytopenias1
1, 2CompletedTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentLeukemias2
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
1, 2CompletedTreatmentLeukemias / Transplantation, Stem Cell1
1, 2CompletedTreatmentMalignancies, Hematologic1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentWiskott-Aldrich Syndrome (WAS)1
1, 2Not Yet RecruitingTreatmentMalignant Lymphomas / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myeloid Leukemia (CML) / Juvenile Myelomonocytic Leukemia (JMML) / Lymphoma (Hodgkin's and Non-Hodgkin's) / Myelodysplastic Syndromes (MDS)1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Mixed-Lineage Acute Leukemias1
1, 2RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL) / Peripheral T-Cell Lymphoma (PTCL) / T-Large Granulocytic Leukemia / T-Lymphoblastic Leukemia/Lymphoma / T-Prolymphocytic Leukemia1
1, 2RecruitingTreatmentGamma C-Deficient SCID / SCID-X1 / X-linked Severe Combined Immunodeficiency / XSCID1
1, 2RecruitingTreatmentGenetic Rare Disease1
1, 2RecruitingTreatmentHigh-risk Medulloblastoma1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic1
1, 2RecruitingTreatmentLeukemias2
1, 2RecruitingTreatmentMalignant Lymphomas2
1, 2RecruitingTreatmentMyeloproliferative Disorders / Primary Myelofibrosis1
1, 2RecruitingTreatmentSevere Combined Immunodeficiency Disease, X-linked1
1, 2RecruitingTreatmentX-Linked Combined Immunodeficiency Diseases1
1, 2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Hematologic Diseases / Lymphoproliferative Disorders / Multiple Myeloma (MM) / Myelodysplastic and Myeloproliferative Disorders / Plasma Cell Dyscrasia1
1, 2TerminatedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome1
1, 2TerminatedTreatmentAnemias / Immunodeficiencies / Leukemias / Malignant Lymphomas / Neuroblastomas1
1, 2TerminatedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1, 2TerminatedTreatmentMultiple Myeloma (MM)2
1, 2Unknown StatusTreatmentBlood And Marrow Transplantation / Leukemias / Lymphoma, Hodgkins / Malignant Lymphomas / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL) / Transplantation Infection1
1, 2Unknown StatusTreatmentChronic Granulomatous Disease (CGD)1
1, 2Unknown StatusTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2Unknown StatusTreatmentLeukemias1
1, 2WithdrawnTreatmentLeukemias1
1, 2WithdrawnTreatmentLymphocyte B CD22 Positive Acute Lymphoblastic Leukemia1
1, 2WithdrawnTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Graft Versus Host Disease (GVHD) / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Disorders / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Immune System Diseases / Leukemia Acute Myeloid Leukemia (AML) / Malignant Lymphomas / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia in Remission1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia With Myelodysplasia-Related Changes / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Leukemia Acute Myeloid Leukemia (AML) / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAdrenoleukodystrophy (ALD) / Alpha Mannosidosis / Aspartylglucosaminuria / Fucosidosis / Hunter Syndrome / Hurler's Syndrome / Krabbe's Disease / Metachromatic Leukodystrophy (MLD) / Mucopolysaccharidosis / Mucopolysaccharidosis VI / Peroxisomal Disorders / Sly Syndrome / Sphingolipidoses1
2Active Not RecruitingTreatmentChronic Granulomatous Disease (CGD)1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Low-Grade / Lymphoma, Mantle-Cell / Small Lymphocytic Lymphoma (SLL) / T-Cell Lymphomas1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes2
2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Leukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentJuvenile Myelomonocytic Leukemia1
2Active Not RecruitingTreatmentLeukemias2
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Transplantation, Stem Cell1
2Active Not RecruitingTreatmentLeukemias / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2CompletedDiagnosticMalignant Lymphomas1
2CompletedScreeningLeukemias / Malignant Lymphomas / Smith-Magenis Syndrome1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myeloid Leukemia in Remission / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Promyelocytic Leukemia (M3) / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Myeloid Leukemia in Remission / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Philadelphia Chromosome Negative Chronic Myelogenous Leukemia / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Multiple Myeloma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Hematopoietic/Lymphoid Cancer / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Allogeneic Haematopoietic Stem Cell Transplantation / Leukemias / Malignant Lymphomas1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2CompletedTreatmentAcute Myelogenous Leukaemia (AML)1
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Erythroleukemia (M6a) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Adult Pure Erythroid Leukemia (M6b) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Burkitt's Lymphoma / Childhood Acute Erythroleukemia (M6) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Leukemia, Prolymphocytic / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Splenic Marginal Zone Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAdult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / De Novo Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)1
2CompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Childhood Acute Myeloid Leukemia in Remission / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
2CompletedTreatmentAgnogenic Myeloid Metaplasia1
2CompletedTreatmentAgnogenic Myeloid Metaplasia / Aplastic Anaemia (AA) / Multiple Myeloma (MM) / Neoplasms, Hematologic / Paroxysmal Hemoglobinuria1
2CompletedTreatmentAllogeneic Marrow Transplant / Leukemias / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentBeta-Thalassemia / Hematologic Diseases / Hematopoietic Stem Cell Transplantation (HSCT) / Sickle Cell Disorders1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentCancer, Breast / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Testicular germ cell tumour / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentChronic Diseases / Leukaemia, Acute / Leukemias / Malignant Lymphomas / Myelodysplasia1
2CompletedTreatmentChronic Myelogenous Leukemia (CML)1
2CompletedTreatmentChronic Myelogenous Leukemia (CML) / Leukemias1
2CompletedTreatmentChronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2CompletedTreatmentChronic Myeloproliferative Disorders1
2CompletedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Multiple Myeloma and Malignant Plasma Cell Neoplasms / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Multiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentCongenital Amegakaryocytic Thrombocytopenia / Congenital Hypoplastic Anemia / Leukemias / Myelodysplastic Syndromes / Severe Congenital Neutropenia1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Inflammatory carcinoma of the breast / Male Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IIIB Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentGraft Versus Host Disease (GVHD)1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Secondary Myelofibrosis1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Neuroblastomas1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes / Thymic Carcinoma1
2CompletedTreatmentHaematological Malignancies1
2CompletedTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders / Thalassaemic disorders1
2CompletedTreatmentHematologic Diseases / Leukemias / Malignant Lymphomas / Plasma Cell Myeloma1
2CompletedTreatmentLeukemias8
2CompletedTreatmentLeukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Myeloproliferative Neoplasms / Plasma Cell Neoplasms1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes2
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Myeloproliferative Disorders / Renal Cancers1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic-Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases2
2CompletedTreatmentLeukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes4
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases3
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentLeukemias / Transplantation, Stem Cell1
2CompletedTreatmentMalignancies, Hematologic2
2CompletedTreatmentMalignant Lymphomas5
2CompletedTreatmentMalignant Lymphomas / Multiple Myeloma (MM)1
2CompletedTreatmentMalignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentMannosidosis / Mucolipidosis Type II (I-cell Disease) / Mucopolysaccharidosis VI / Type 1 Mucopolysaccharidosis1
2CompletedTreatmentMultiple Myeloma (MM)1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm5
2CompletedTreatmentNeuroblastomas1
2CompletedTreatmentPlasma Cell Myeloma1
2CompletedTreatmentSarcomas1
2CompletedTreatmentSickle Cell Disorders1
2Not Yet RecruitingTreatmentAnemias / ASXL1 Gene Mutation / EZH2 Gene Mutation / IDH1 Gene Mutation / IDH2 Gene Mutation / Plasma Cell Myeloma / Primary Myelofibrosis / Recurrent Plasma Cell Myeloma / Secondary Myelofibrosis / Thrombocytopenias1
2RecruitingNot AvailableMyeloid Leukemias1
2RecruitingPreventionAcute Leukemia in Remission / Chronic Myeloid Leukemia (CML) / Chronic Myelomonocytic Leukemia / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL) / Primary Myelofibrosis1
2RecruitingPreventionChronic Myeloid Leukemia (CML) / Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Myelodysplastic Syndromes1
2RecruitingSupportive CareChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Follicular Lymphoma (FL) / Graft Versus Host Disease (GVHD) / Leukaemia, Acute / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / Secondary Myelodysplastic Syndromes1
2RecruitingTreatmentAcute Biphenotypic Leukemia (ABL) / Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma / Acute Myelogenous Leukaemia (AML) / Acute Undifferentiated Leukemia (AUL) / Chemotherapy-sensitive Lymphoma / Chronic Lymphocytic Leukaemia (CLL) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Myeloproliferative Syndromes / Non-Hodgkin's Lymphoma (NHL) / Other Diseases of Blood and Blood-Forming Organs1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Congenital Hypoplastic Anemia / Myelodysplastic Syndromes (MDS) / Severe Marrow Failure1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Aplastic Anaemia (AA) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Essential Thrombocythemia (ET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Juvenile Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia / Refractory Anemia With Ringed Sideroblasts / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Urticaria Pigmentosa / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentBeta Thalassemia / Bone Marrow Failure / Histiocytosis / Immunodeficiencies / Inborn Errors of Metabolism / Leukemias / Malignant Lymphomas / Sickle Cell Disorders1
2RecruitingTreatmentBeta Thalassemia / Sickle Cell Disorders1
2RecruitingTreatmentBone Marrow Failure Syndromes / Congenital Immunodeficiency / Haemoglobinopathies congenital / Inborn Errors of Metabolism1
2RecruitingTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndrome / De Novo Myelodysplastic Syndrome / Leukemias / Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Childhood Acute Myeloid Leukemia / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
2RecruitingTreatmentChronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2RecruitingTreatmentCongenital Hypoplastic Anemia1
2RecruitingTreatmentDOCK8 Deficiency1
2RecruitingTreatmentEwing's Sarcoma (ES)1
2RecruitingTreatmentExtranodal NK-T-CELL LYMPHOMA / NK/T Cell Lymphoma1
2RecruitingTreatmentGATA2 / Immunodeficiencies / Smith-Magenis Syndrome1
2RecruitingTreatmentGraft Survival / HLA-mismatched Bone Marrow Transplantation / Myeloablative Conditioning / Transplantion, Bone Marrow1
2RecruitingTreatmentHaematological Malignancies1
2RecruitingTreatmentHematological Diseases1
2RecruitingTreatmentHematopoietic Stem Cell Transplant (HSCT) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentHematopoietic/Lymphoid Cancer1
2RecruitingTreatmentLeukaemia, Acute1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
2RecruitingTreatmentLeukemias1
2RecruitingTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
2RecruitingTreatmentLeukemias / Malignant Lymphomas / Myeloproliferative Disorders / Plasma Cell Myeloma1
2RecruitingTreatmentLymphoma, Extranodal NK-T-Cell / T-Cell Non-Hodgkin Lymphoma1
2RecruitingTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentMalignant Lymphomas1
2RecruitingTreatmentMultiple Myeloma (MM)3
2RecruitingTreatmentNeuroblastomas1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentPrimary Myelofibrosis / Secondary Myelofibrosis1
2RecruitingTreatmentSevere Immunodeficiency Diseases1
2RecruitingTreatmentSickle Cell Disorders1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelocytic Leukemia / Chronic Myelocytic Leukemia / Granulocytic Sarcoma / Hodgkin's or Non-Hodgkin's Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Aplastic Anaemia (AA) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentAcute Myelogenous Leukaemia (AML) / Refractory Acute Myelogenous Leukemia1
2TerminatedTreatmentAlpha Mannosidosis / Aspartylglucosaminuria / Fucosidosis / Hurler's Syndrome / Krabbe's Disease / Mucopolysaccharidosis VI / Niemann-Pick Disease Type B / Niemann-Pick Disease, Type C / Sly Syndrome / Sphingolipidoses / Wolman's Disease1
2TerminatedTreatmentAplastic Anaemia (AA) / Leukemias / Malignant Lymphomas / Multiple Myeloma (MM)1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Hodgkins Disease (HD) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphoblastic, Acute / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood1
2TerminatedTreatmentHaemoglobinopathies congenital / Hemoglobin SC Disease / Sickle Cell Disorders / Thalassaemic disorders / Thalassemia Major (TM)1
2TerminatedTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders / Thalassaemic disorders1
2TerminatedTreatmentHematological Diseases1
2TerminatedTreatmentLeukemias2
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndrome1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2TerminatedTreatmentLeukemias / Malignant Lymphomas / Other Haematological Diseases1
2TerminatedTreatmentMalignancies, Hematologic2
2TerminatedTreatmentMyeloproliferative Disorders1
2TerminatedTreatmentOsteopetrosis1
2TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2TerminatedTreatmentSickle Cell Disorders1
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2Unknown StatusSupportive CareChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2Unknown StatusTreatmentChildhood Langerhans Cell Histiocytosis / Congenital Hypoplastic Anemia / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2Unknown StatusTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Precancerous Conditions1
2Unknown StatusTreatmentHematopoietic Stem Cell Transplantation (HSCT)1
2Unknown StatusTreatmentMultiple Myeloma (MM)1
2Unknown StatusTreatmentNeoplasms, Hematologic / Tumors, Solid1
2Unknown StatusTreatmentNeuroblastomas1
2Unknown StatusTreatmentNon Hodgkin Lymphoma (NHL)1
2Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)2
2Unknown StatusTreatmentRefractory Follicular Lymphoma1
2Unknown StatusTreatmentSigns and Symptoms, Respiratory1
2WithdrawnSupportive CareGraft Versus Host Disease (GVHD) / Leukemias / Myelodysplastic Syndromes1
2WithdrawnTreatmentAnemias / Chronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2WithdrawnTreatmentLeukemias1
2WithdrawnTreatmentMalignant Lymphomas1
2WithdrawnTreatmentNeuroblastomas1
2WithdrawnTreatmentPlasma Cell Myeloma1
2, 3Active Not RecruitingTreatmentChediak-Higashi Syndrome / Griscelli Syndrome / Hematologic Diseases / Histiocytosis, Langerhans-Cell / Immunologic Diseases / Lymphohistiocytosis, Hemophagocytic / X-Linked Lymphoproliferative Disorders1
2, 3Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2, 3Active Not RecruitingTreatmentCongenital Hypoplastic Anemia / Severe Congenital Neutropenia / Shwachman-Diamond Syndrome / Sickle Cell Disorders / Thalassaemic disorders1
2, 3CompletedTreatmentAdrenoleukodystrophy / Fucosidosis / Gangliosidosis, GM1 / Gaucher's Disease / Juvenile Neuronal Ceroid Lipofuscinosis / Leukodystrophy, Globoid Cell / Metachromatic Leukodystrophy / Sandhoff Disease / Sphingomyelin Lipidosis / Tay Sachs Disease / Wolman's Disease1
2, 3CompletedTreatmentCongenital Hypoplastic Anemia / Kostmann's Neutropenia / Shwachman-Diamond Syndrome1
2, 3CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2, 3RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Allogeneic peripheral haematopoietic stem cell transplant / Busulfan / Total Body Irradiation1
2, 3RecruitingTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Conditioning / Myelodysplastic Syndrome1
2, 3RecruitingTreatmentAutologous Hematopoietic Stem Cell Transplantation / Conditioning / Leukemia Acute Myeloid Leukemia (AML)1
2, 3RecruitingTreatmentAutologous Hematopoietic Stem Cell Transplantation / Conditioning / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2, 3RecruitingTreatmentLeukemias1
2, 3TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphocytic, Acute / Smith-Magenis Syndrome1
2, 3Unknown StatusTreatmentOsteopetrosis1
2, 3Unknown StatusTreatmentSevere Osteopetrosis1
3Active Not RecruitingTreatmentDisorder Related to Bone Marrow Transplantation / Leukemias / Transplantation Infection1
3Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
3Active Not RecruitingTreatmentLeukemias1
3Active Not RecruitingTreatmentPlasma Cell Myeloma1
3CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Acute Myeloid Leukemia/Transient Myeloproliferative Disorder / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
3CompletedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Erythroid Leukemia (M6) / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Childhood Acute Basophilic Leukemia / Childhood Acute Eosinophilic Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentCancer, Breast1
3CompletedTreatmentChildhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignant Lymphomas1
3CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndrome1
3CompletedTreatmentLeukemias2
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
3CompletedTreatmentMultiple Myeloma (MM)1
3Not Yet RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / NMYC Gene Amplification / Recurrent Neuroblastoma1
3RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Chronic Myelogenous Leukemia (CML) / Myelodysplastic Syndrome / Myeloid Malignancy / Myeloproliferative Disorders1
3RecruitingTreatmentEwing's Sarcoma (ES)2
3RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3RecruitingTreatmentNeuroblastomas1
3TerminatedTreatmentLeukemia, Myelocytic, Acute1
3TerminatedTreatmentLeukemias1
3Unknown StatusTreatmentLeukemias5
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
3Unknown StatusTreatmentNeuroblastomas2
3Unknown StatusTreatmentNonneoplastic Condition1
3Unknown StatusTreatmentSarcomas1
4CompletedTreatmentLeukemia, Lymphocytic / Malignant Lymphomas / Myelodysplastic Syndromes / Myeloproliferative Disorders / Plasma Cell Myeloma1
4Not Yet RecruitingTreatmentChronic Leukemias / Juvenile Myelomonocytic Leukemia / Leukaemia, Acute / Myelodysplastic Syndrome1
4Not Yet RecruitingTreatmentLeukemias1
4RecruitingTreatmentThalassemia Major (TM)1
Not AvailableActive Not RecruitingTreatmentAIDS Related Non-Hodgkin Lymphoma / AIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableActive Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Plasma Cell Neoplasms / Primary Systemic Amyloidosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Neuroblastoma / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Regional Neuroblastoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentAdult Central Nervous System Germ Cell Tumor / Adult Rhabdomyosarcoma / Childhood Central Nervous System Germ Cell Tumor / Childhood Soft Tissue Sarcoma / Ewing's Sarcoma (ES) / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Ovarian Mixed Germ Cell Tumor / Previously Untreated Childhood Rhabdomyosarcoma / Recurrent Adult Brain Tumor / Recurrent Adult Soft Tissue Sarcoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Malignant Germ Cell Tumor / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Recurrent Childhood Visual Pathway Glioma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Extragonadal Germ Cell Tumor / Recurrent Extragonadal Non-seminomatous Germ Cell Tumor / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Neuroblastoma / Recurrent Ovarian Germ Cell Tumor / Recurrent Wilms Tumor and Other Childhood Kidney Tumors / Tumors, Solid / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
Not AvailableActive Not RecruitingTreatmentLeukemias1
Not AvailableActive Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
Not AvailableActive Not RecruitingTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas1
Not AvailableCompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableCompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Leukemias / Myelodysplasia1
Not AvailableCompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Myeloid Leukemia in Remission / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Myelodysplastic Syndrome With Isolated Del(5q) / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Secondary Myelofibrosis / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
Not AvailableCompletedTreatmentAgnogenic Myeloid Metaplasia / Aplastic Anaemia (AA) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Leukaemia, Acute / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphocytic / Malignant Lymphomas / Multiple Myeloma (MM) / Myeloproliferative Disorders / Polycythemia Vera (PV)1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors1
Not AvailableCompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
Not AvailableCompletedTreatmentDisseminated Neuroblastoma / Ganglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableCompletedTreatmentHematological Neoplasms / Hematopoietic Stem Cell Transplantation (HSCT)1
Not AvailableCompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableCompletedTreatmentMalignant Lymphomas / Neuroblastomas / Tumors, Central Nervous System / Wilms' tumor1
Not AvailableCompletedTreatmentNeutropenias / Red-Cell Aplasia, Pure / Sickle Cell Disorders / Thalassemia Major (TM)1
Not AvailableNo Longer AvailableNot AvailableLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous Conditions / Secondary Myelofibrosis1
Not AvailableRecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
Not AvailableRecruitingTreatmentAtypical Teratoid/Rhabdoid Tumor (AT/RT) / CNS Tumors / Ewing's Family Tumors / Germ Cell Tumors / Hepatoblastomas / Medulloblastomas / Primary Malignant Brain Neoplasms / Renal Tumors / Retinoblastoma / Rhabdomyosarcomas / Soft Tissue Sarcoma (STS) / Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)1
Not AvailableRecruitingTreatmentBare Lymphocyte Syndrome / CD40 Ligand Deficiency / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Griscelli Syndrome / Hyper IgM Syndrome / Langerhan's Cell Histiocytosis / Lymphohistiocytosis, Hemophagocytic / Omenn's Syndrome / Reticular Dysgenesis / SCID / Wiskott-Aldrich Syndrome (WAS) / X-Linked Lymphoproliferative Disease1
Not AvailableRecruitingTreatmentCongenital Pediatric Disorders1
Not AvailableRecruitingTreatmentGraft Versus Host Disease (GVHD) / Hematopoietic/Lymphoid Cancer1
Not AvailableRecruitingTreatmentHaematological disorders / Haemoglobinopathies congenital / Immunodeficiencies1
Not AvailableRecruitingTreatmentHodgkins Disease (HD) / JMML / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphocytic, Acute / Leukemia, Lymphocytic, Chronic / Leukemia,Myeloid, Chronic / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Smith-Magenis Syndrome1
Not AvailableRecruitingTreatmentMyeloid Hematological Malignancies1
Not AvailableSuspendedTreatmentBone Marrow Failure Syndromes / Congenital Immunodeficiency / Metabolic Diseases / Myeloid Malignancy / Severe Immune Dysregulation / Transfusion-dependent Red Blood Cell (RBC) Defect1
Not AvailableSuspendedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableTerminatedOtherLeukemia Acute Myeloid Leukemia (AML)1
Not AvailableTerminatedTreatmentBruton's agammaglobulinemia / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Immunologic Deficiency Syndromes / Leukocyte Adhesion Deficiency Syndrome / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Virus-Associated Hemophagocytic Syndrome / Wiskott-Aldrich Syndrome (WAS) / X-Linked Hyper IgM Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Congenital Hypoplastic Anemia / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Sarcomas1
Not AvailableTerminatedTreatmentEpidermolysis Bullosa1
Not AvailableTerminatedTreatmentHemoglobin SC / Sickle Cell Disorders1
Not AvailableTerminatedTreatmentThalassaemic disorders1
Not AvailableUnknown StatusSupportive CareGraft Versus Host Disease (GVHD) / Leukemias1
Not AvailableUnknown StatusTreatmentChediak-Higashi Syndrome / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Lymphohistiocytosis, Hemophagocytic / Virus-Associated Hemophagocytic Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableUnknown StatusTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Renal Cancers1
Not AvailableUnknown StatusTreatmentLeukemias1
Not AvailableUnknown StatusTreatmentMalignancies, Hematologic1
Not AvailableWithdrawnTreatmentAdult Supratentorial Primitive Neuroectodermal Tumor (PNET) / Ewing Sarcoma of Bone / Extraosseous Ewing Sarcoma / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
Not AvailableWithdrawnTreatmentAgnogenic Myeloid Metaplasia / MF1

Pharmacoeconomics

Manufacturers
  • Otsuka pharmaceutical co ltd
  • Glaxosmithkline
Packagers
Dosage forms
FormRouteStrength
Injection, solution, concentrateIntravenous6 mg/mL
InjectionIntravenous6 mg/mL
SolutionIntravenous6 mg
TabletOral2 mg
Tablet, film coatedOral2 mg/1
Prices
Unit descriptionCostUnit
Busulfex 6 mg/ml vial115.08USD ml
Myleran 2 mg tablet4.55USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5430057No1994-03-302014-03-30Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)106-107Timmis, G.M.; U S . Patent 2,917,432; December 15, 1959; assigned to Burroughs Wellcome & Co., Inc.
water solubility6.9E+004 mg/LNot Available
logP-0.52HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility5.16 mg/mLALOGPS
logP-0.9ALOGPS
logP-0.76ChemAxon
logS-1.7ALOGPS
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area86.74 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity49.57 m3·mol-1ChemAxon
Polarizability23.64 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9059
Blood Brain Barrier+0.9674
Caco-2 permeable-0.5956
P-glycoprotein substrateNon-substrate0.7556
P-glycoprotein inhibitor INon-inhibitor0.7224
P-glycoprotein inhibitor IINon-inhibitor0.9651
Renal organic cation transporterNon-inhibitor0.8617
CYP450 2C9 substrateNon-substrate0.8656
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateNon-inhibitor0.8678
CYP450 2C9 inhibitorNon-inhibitor0.85
CYP450 2D6 inhibitorNon-inhibitor0.9159
CYP450 2C19 inhibitorNon-inhibitor0.7723
CYP450 3A4 inhibitorNon-inhibitor0.9855
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9069
Ames testAMES toxic0.9305
CarcinogenicityCarcinogens 0.7585
BiodegradationReady biodegradable0.5
Rat acute toxicity2.3207 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6005
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0390000000-19a6e15d2bf397b244b1
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-1490000000-7895468c598e6a0480c8
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as organosulfonic acid esters. These are esters of sulfonic acid, which have the general structure RS(=O)2OR' (R,R' = organyl, not H).
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic sulfonic acids and derivatives
Sub Class
Organosulfonic acids and derivatives
Direct Parent
Organosulfonic acid esters
Alternative Parents
Sulfonic acid esters / Sulfonyls / Methanesulfonates / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Organosulfonic acid ester / Sulfonic acid ester / Sulfonyl / Methanesulfonate / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organosulfur compound / Organooxygen compound / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
methanesulfonate ester (CHEBI:28901)

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Yes
Actions
Cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Morales-Ramirez P, Gonzalez-Beltran F: Different behavior of SCE-eliciting lesions induced by low and high doses of busulfan. Environ Mol Mutagen. 2007 Oct;48(8):706-14. [PubMed:17896789]
  4. Valdez BC, Andersson BS: Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies. Environ Mol Mutagen. 2010 Jul;51(6):659-68. doi: 10.1002/em.20603. [PubMed:20577993]
  5. Hall AG, Tilby MJ: Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev. 1992 Sep;6(3):163-73. [PubMed:1422285]
  6. Ciurea SO, Andersson BS: Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 May;15(5):523-36. doi: 10.1016/j.bbmt.2008.12.489. Epub 2009 Feb 12. [PubMed:19361744]
  7. McCune JS, Holmberg LA: Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):957-69. doi: 10.1517/17425250903107764. [PubMed:19611402]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glutathione transferase activity
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name
GSTA2
Uniprot ID
P09210
Uniprot Name
Glutathione S-transferase A2
Molecular Weight
25663.675 Da
References
  1. Vassord C, Lapoumeroulie C, Koumaravelou K, Srivastava A, Krishnamoorthy R: Endothelial cells do not express GSTA1: potential relevance to busulfan-mediated endothelial damage during haematopoietic stem cell transplantation. Eur J Haematol. 2008 Apr;80(4):299-302. doi: 10.1111/j.1600-0609.2008.01031.x. Epub 2008 Jan 14. [PubMed:18194479]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glutathione transferase activity
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name
GSTA1
Uniprot ID
P08263
Uniprot Name
Glutathione S-transferase A1
Molecular Weight
25630.785 Da
References
  1. Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, Iga T: Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta. 2006 Jun;368(1-2):93-8. Epub 2006 Jan 31. [PubMed:16448639]
  2. Elhasid R, Krivoy N, Rowe JM, Sprecher E, Adler L, Elkin H, Efrati E: Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010 Dec 1;55(6):1172-9. doi: 10.1002/pbc.22739. [PubMed:20672371]
  3. Vassord C, Lapoumeroulie C, Koumaravelou K, Srivastava A, Krishnamoorthy R: Endothelial cells do not express GSTA1: potential relevance to busulfan-mediated endothelial damage during haematopoietic stem cell transplantation. Eur J Haematol. 2008 Apr;80(4):299-302. doi: 10.1111/j.1600-0609.2008.01031.x. Epub 2008 Jan 14. [PubMed:18194479]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein homodimerization activity
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name
GSTM1
Uniprot ID
P09488
Uniprot Name
Glutathione S-transferase Mu 1
Molecular Weight
25711.555 Da
References
  1. Czerwinski M, Gibbs JP, Slattery JT: Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9. [PubMed:8886613]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
S-nitrosoglutathione binding
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name
GSTP1
Uniprot ID
P09211
Uniprot Name
Glutathione S-transferase P
Molecular Weight
23355.625 Da
References
  1. Czerwinski M, Gibbs JP, Slattery JT: Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9. [PubMed:8886613]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Leukotriene-c4 synthase activity
Specific Function
Can catalyze the production of LTC4 from LTA4 and reduced glutathione. Can catalyze the conjugation of 1-chloro-2,4-dinitrobenzene with reduced glutathione.
Gene Name
MGST2
Uniprot ID
Q99735
Uniprot Name
Microsomal glutathione S-transferase 2
Molecular Weight
16620.4 Da
References
  1. Harkey MA, Czerwinski M, Slattery J, Kiem HP: Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan. Cancer Invest. 2005;23(1):19-25. [PubMed:15779864]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49